429 reports of this reaction
2.1% of all TOBRAMYCIN SULFATE reports
#9 most reported adverse reaction
HOSPITALISATION is the #9 most commonly reported adverse reaction for TOBRAMYCIN SULFATE, manufactured by Fresenius Kabi USA, LLC. There are 429 FDA adverse event reports linking TOBRAMYCIN SULFATE to HOSPITALISATION. This represents approximately 2.1% of all 20,334 adverse event reports for this drug.
Patients taking TOBRAMYCIN SULFATE who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is a less commonly reported adverse event for TOBRAMYCIN SULFATE, but still significant enough to appear in the safety profile.
In addition to hospitalisation, the following adverse reactions have been reported for TOBRAMYCIN SULFATE:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 429 FDA reports for TOBRAMYCIN SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 2.1% of all adverse event reports for TOBRAMYCIN SULFATE, making it a notable side effect.
If you experience hospitalisation while taking TOBRAMYCIN SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.